Renalytix AI PLC ADR (RNLX): Price and Financial Metrics


Renalytix AI PLC ADR (RNLX): $32.79

-0.36 (-1.09%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

RNLX Stock Price Chart Interactive Chart >

Price chart for RNLX

RNLX Price/Volume Stats

Current price $32.79 52-week high $35.71
Prev. close $33.15 52-week low $9.91
Day low $31.80 Volume 85,849
Day high $33.12 Avg. volume 124,856
50-day MA $30.26 Dividend yield N/A
200-day MA $21.09 Market Cap 1.18B

Renalytix AI PLC ADR (RNLX) Company Bio


Renalytix AI Plc manufactures medical devices and equipment. It offers artificial intelligence for kidney disease. The company was founded on March 15,2018 and is headquartered in Penarth, the United Kingdom.


RNLX Latest News Stream


Event/Time News Detail
Loading, please wait...

RNLX Latest Social Stream


Loading social stream, please wait...

View Full RNLX Social Stream

Latest RNLX News From Around the Web

Below are the latest news stories about Renalytix AI plc that investors may wish to consider to help them evaluate RNLX as an investment opportunity.

Renalytix AI plc (RNLX) CEO James McCullough on Q3 2021 Results - Earnings Call Transcript

Renalytix AI plc (RNLX) Q3 2021 Earnings Conference Call June 15, 2021 08:30 ET Company Participants Carrie Mendivil - Investor Relations James McCullough - Co-Founder and Chief Executive Officer Tom McLain - President James Sterling - Chief Financial Officer Conference Call Participants Dan Arias - Stifel Tycho Peterson - JPMorgan...

SA Transcripts on Seeking Alpha | June 15, 2021

Renalytix Reports Financial Results for Third Quarter of Fiscal Year 2021

NEW YORK, June 15, 2021 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX) (“Renalytix” or the “Company”) today reported financial results for the quarter and nine months ended March 31, 2021. Recent Highlights Partnership announced with University of Utah health system to improve kidney health and reduce the risk of kidney failure for large-scale populations in the earliest stages of kidney disease. KidneyIntelX to be integrated with the university electronic health records (EHR) s

Yahoo | June 15, 2021

Renalytix to Report Financial Results for Fiscal Third Quarter 2021 and Provide Corporate Update

Announces Change of Auditor to Ernst & Young LLPNEW YORK, June 10, 2021 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX) today announced the Company will release fiscal third quarter 2021 financial results on Tuesday, June 15, 2021, before market open. The Company will host a corresponding conference call and live webcast at 8:30 a.m. (EDT) / 1:30 p.m. (BST) to discuss the results and provide a corporate update. Conference Call Details:US/Canada Participant Toll-Free Dial-In Numbe

Yahoo | June 10, 2021

Leadership Additions Announced to Support Expanding US Government and Healthcare Provider KidneyIntelX Deployment

Enabling expertise in sales, population health and value-driven care modelsNEW YORK and SALT LAKE CITY, June 07, 2021 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX) today announced a series of key hires to drive its commercialization strategy in the United States market in light of the recently announced Federal Government General Service Administration payment contract and additional large healthcare system partnerships. The combined background and experience of the new leaders

Yahoo | June 7, 2021

Kantaro's Semi-Quantitative Antibody Test Kit Receives Health Canada Authorization Under the COVID-19 Interim Order

Kantaro Biosciences, LLC (Kantaro), a joint venture between the Mount Sinai Health System and RenalytixAI (LSE: RENS / NASDAQ: RNLX), and its commercial partner Bio-Techne Corporation (NASDAQ: TECH), have received Health Canada Authorization under the COVID-19 Interim Order for COVID-SeroKlir, its semi-quantitative SARS-CoV-2 IgG antibody test kit.

Yahoo | June 2, 2021

Read More 'RNLX' Stories Here

RNLX Price Returns

1-mo 5.23%
3-mo 10.70%
6-mo 147.47%
1-year N/A
3-year N/A
5-year N/A
YTD 104.94%
2020 N/A
2019 N/A
2018 N/A
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7089 seconds.